Please login to the form below

Not currently logged in
Email:
Password:

LentiGlobin

This page shows the latest LentiGlobin news and features for those working in and with pharma, biotech and healthcare.

bluebird bio aiming to separate business units by year-end

bluebird bio aiming to separate business units by year-end

In April, bluebird bio also announced that it is anticipating a potential lift of all clinical holds on its LentiGlobin gene therapy for sickle cell disease (SCD) following the re-classification ... bluebird bio also previously reported that it is

Latest news

More from news
Approximately 6 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    LentiGlobin (betibeglogene darolentivec), an Orphan Drug and Breakthrough Therapy from Bluebird Bio, corrects the defect causing beta thalassemia, a blood disorder that causes life-threatening anaemia. ... The initial studies for LentiGlobin in

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    7. LentiGlobin TDT – a gene therapy first for Europe. Gene therapy company Bluebird Bio is on course to gain approval for its first product this year – and Europe is expected to ... The Cambridge, Massachusetts-based firm filed its gene therapy

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    The Cambridge, Mass-based company is set to file the first of its four candidates, LentiGlobin TDT, a gene therapy for patients with the rare blood disorder beta thalassemia, by the ... Pharmaceutical Market Europe spoke to Bluebird’s CEO Nick Leschly

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....